Research ExplorerPublicationsHigh plasma dimethylarginine levels are associated with adve...

High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke

Standard

High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke. / Worthmann, Hans; Chen, Shufen; Martens-Lobenhoffer, Jens; Li, Na; Deb-Chatterji, Milani; Tryc, Anita Blanka; Goldbecker, Annemarie; Dong, Qiang; Kielstein, Jan Thomas; Bode-Böger, Stefanie Margarethe; Weissenborn, Karin.

In: J ATHEROSCLER THROMB, Vol. 18, No. 9, 2011, p. 753-61.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Worthmann, H, Chen, S, Martens-Lobenhoffer, J, Li, N, Deb-Chatterji, M, Tryc, AB, Goldbecker, A, Dong, Q, Kielstein, JT, Bode-Böger, SM & Weissenborn, K 2011, 'High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke', J ATHEROSCLER THROMB, vol. 18, no. 9, pp. 753-61.

APA

Worthmann, H., Chen, S., Martens-Lobenhoffer, J., Li, N., Deb-Chatterji, M., Tryc, A. B., Goldbecker, A., Dong, Q., Kielstein, J. T., Bode-Böger, S. M., & Weissenborn, K. (2011). High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke. J ATHEROSCLER THROMB, 18(9), 753-61.

Vancouver

Worthmann H, Chen S, Martens-Lobenhoffer J, Li N, Deb-Chatterji M, Tryc AB et al. High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke. J ATHEROSCLER THROMB. 2011;18(9):753-61.

Bibtex

@article{26bf94f4df3743eca09e1c142e150b0b,
title = "High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke",
abstract = "AIM: Increased levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been observed in patients with cardiovascular risk factors and atherosclerosis and in patients with a history of stroke. The role of ADMA and its analogue symmetric dimethylarginine (SDMA) in acute ischemic stroke is yet unclear. We hypothesized that plasma dimethylarginine levels increase in the hyper-acute phase after ischemic stroke and that their time course is related to stroke outcome.METHODS: Plasma dimethylarginines ADMA and SDMA and L-arginine levels were measured in 67 patients at 6, 12, 24 hours, as well as 3 and 7 days after stroke onset using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS). Data were compared to control data from 32 age-adjusted healthy volunteers. Clinical outcome was assessed using the modified Rankin Scale (mRS) at 90 days after stroke.RESULTS: At baseline, plasma ADMA levels were higher in stroke patients than in controls, whereas plasma SDMA and L-arginine levels did not differ from control subjects. The time courses of ADMA and SDMA were related to the clinical outcome. Binary logistic regression analysis showed that ADMA levels of ≥ 0.566 µmol/L at day 3, ≥ 0.530 µmol/L at day 7 and SDMA levels of ≥ 0.59 µmol/L at 24 hours predicted an unfavorable clinical outcome.CONCLUSIONS: An increase of both ADMA and SDMA plasma levels within the first 72 hours after the onset of ischemic stroke predicts a poor outcome.",
keywords = "Aged, Arginine, Case-Control Studies, Chromatography, High Pressure Liquid, Female, Humans, Male, Middle Aged, Prospective Studies, Reproducibility of Results, Stroke, Tandem Mass Spectrometry, Journal Article, Research Support, Non-U.S. Gov't",
author = "Hans Worthmann and Shufen Chen and Jens Martens-Lobenhoffer and Na Li and Milani Deb-Chatterji and Tryc, {Anita Blanka} and Annemarie Goldbecker and Qiang Dong and Kielstein, {Jan Thomas} and Bode-B{\"o}ger, {Stefanie Margarethe} and Karin Weissenborn",
year = "2011",
language = "English",
volume = "18",
pages = "753--61",
journal = "J ATHEROSCLER THROMB",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "9",

}

RIS

TY - JOUR

T1 - High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke

AU - Worthmann, Hans

AU - Chen, Shufen

AU - Martens-Lobenhoffer, Jens

AU - Li, Na

AU - Deb-Chatterji, Milani

AU - Tryc, Anita Blanka

AU - Goldbecker, Annemarie

AU - Dong, Qiang

AU - Kielstein, Jan Thomas

AU - Bode-Böger, Stefanie Margarethe

AU - Weissenborn, Karin

PY - 2011

Y1 - 2011

N2 - AIM: Increased levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been observed in patients with cardiovascular risk factors and atherosclerosis and in patients with a history of stroke. The role of ADMA and its analogue symmetric dimethylarginine (SDMA) in acute ischemic stroke is yet unclear. We hypothesized that plasma dimethylarginine levels increase in the hyper-acute phase after ischemic stroke and that their time course is related to stroke outcome.METHODS: Plasma dimethylarginines ADMA and SDMA and L-arginine levels were measured in 67 patients at 6, 12, 24 hours, as well as 3 and 7 days after stroke onset using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS). Data were compared to control data from 32 age-adjusted healthy volunteers. Clinical outcome was assessed using the modified Rankin Scale (mRS) at 90 days after stroke.RESULTS: At baseline, plasma ADMA levels were higher in stroke patients than in controls, whereas plasma SDMA and L-arginine levels did not differ from control subjects. The time courses of ADMA and SDMA were related to the clinical outcome. Binary logistic regression analysis showed that ADMA levels of ≥ 0.566 µmol/L at day 3, ≥ 0.530 µmol/L at day 7 and SDMA levels of ≥ 0.59 µmol/L at 24 hours predicted an unfavorable clinical outcome.CONCLUSIONS: An increase of both ADMA and SDMA plasma levels within the first 72 hours after the onset of ischemic stroke predicts a poor outcome.

AB - AIM: Increased levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been observed in patients with cardiovascular risk factors and atherosclerosis and in patients with a history of stroke. The role of ADMA and its analogue symmetric dimethylarginine (SDMA) in acute ischemic stroke is yet unclear. We hypothesized that plasma dimethylarginine levels increase in the hyper-acute phase after ischemic stroke and that their time course is related to stroke outcome.METHODS: Plasma dimethylarginines ADMA and SDMA and L-arginine levels were measured in 67 patients at 6, 12, 24 hours, as well as 3 and 7 days after stroke onset using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS). Data were compared to control data from 32 age-adjusted healthy volunteers. Clinical outcome was assessed using the modified Rankin Scale (mRS) at 90 days after stroke.RESULTS: At baseline, plasma ADMA levels were higher in stroke patients than in controls, whereas plasma SDMA and L-arginine levels did not differ from control subjects. The time courses of ADMA and SDMA were related to the clinical outcome. Binary logistic regression analysis showed that ADMA levels of ≥ 0.566 µmol/L at day 3, ≥ 0.530 µmol/L at day 7 and SDMA levels of ≥ 0.59 µmol/L at 24 hours predicted an unfavorable clinical outcome.CONCLUSIONS: An increase of both ADMA and SDMA plasma levels within the first 72 hours after the onset of ischemic stroke predicts a poor outcome.

KW - Aged

KW - Arginine

KW - Case-Control Studies

KW - Chromatography, High Pressure Liquid

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Reproducibility of Results

KW - Stroke

KW - Tandem Mass Spectrometry

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

M3 - SCORING: Journal article

C2 - 21566344

VL - 18

SP - 753

EP - 761

JO - J ATHEROSCLER THROMB

JF - J ATHEROSCLER THROMB

SN - 1340-3478

IS - 9

ER -